Bipolar I
Resources for Patients and Caregivers
Bipolar I Disorder— defined by manic episodes that last at least 7 days, or by manic symptoms that are so severe that the person needs immediate hospital care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks.
Cluster Number:
Wiki Number: 08-Bipolar I
Diagnosis: This requires just one full manic episode where the individual may be “high” for several days.
US Patients: 1% of the US population in their lifetimes.
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: Typically it will be followed by one or more depressive stretches of time.
Progression: Relatively good, may last 6 months or 25% go to PTSD or Major Depressive Disorder
Causes:
Medications:Can be reduced by other prescribed drugs.
Therapies:
Youtube Video: Faces of Bipolar Disorder (PART 2) “Bipolar Type 1”
Amazon or Library Book: Bipolar Disorder 1
How to Survive and Thrive
Click the book to link or order from Amazon.
Support Group: dsballiance.org; 800-326-3632
(Depression and Bipolar Support Alliance)
Contact your local Social Security offic for possible Disability Benefits through their Disability Determination Services,
Section 12.04.
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Pure-Water-Fed Forward-Bias Bipolar Membrane CO(2) Electrolyzerby Matthias Heßelmann on May 7, 2024
Coupling renewable electricity to reduce carbon dioxide (CO(2)) electrochemically into carbon feedstocks offers a promising pathway to produce chemical fuels sustainably. While there has been success in developing materials and theory for CO(2) reduction, the widespread deployment of CO(2) electrolyzers has been hindered by challenges in the reactor design and operational stability due to CO(2) crossover and (bi)carbonate salt precipitation. Herein, we design asymmetrical bipolar membranes...
- A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophreniaby Panneer Selvan on May 7, 2024
Management of negative symptoms is one of the most challenging and important unmet needs of schizophrenia treatment. Negative symptoms together with positive symptoms result in significant psychosocial impairment and poor quality of life. Existing studies on atypical antipsychotics reported limited treatment adherence due to higher prevalence of treatment-emergent adverse events, such as diabetes, weight gain, hyperlipidemia, hyperprolactinemia and hypertension. A compound with greater affinity...
- Comparison of short-term efficacy of two bipolar radiofrequency ablation forceps for rheumatic heart disease concomitant with atrial fibrillationby Ning Zhang on May 7, 2024
CONCLUSIONS: The two bipolar radiofrequency ablation forceps compared in the study are safe and effective in treating patients of RHD concomitant with AF, and the ablation forceps by AtriCure may be more effective in restoring SR in the short term.
- A cross ancestry genetic study of psychiatric disorders from Indiaby Bharath Holla on May 7, 2024
Genome-wide association studies across diverse populations may help validate and confirm genetic contributions to risk of disease. We estimated the extent of population stratification as well as the predictive accuracy of polygenic scores (PGS) derived from European samples to a data set from India. We analysed 2685 samples from two data sets, a population neurodevelopmental study (cVEDA) and a hospital-based sample of bipolar affective disorder (BD) and obsessive-compulsive disorder (OCD)....